COVID-19 Breakthrough Infection Among Immunocompromised Persons

Alfred H.J. Kim; Mary C. Nakamura

doi:10.1001/jamainternmed.2021.7033

COVID-19 Breakthrough Infection Among Immunocompromised Persons

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	163-164
Number of pages	2
Journal	JAMA Internal Medicine
Volume	182
Issue number	2
DOIs	https://doi.org/10.1001/jamainternmed.2021.7033
State	Published - Feb 2022

Access to Document

10.1001/jamainternmed.2021.7033

Cite this

@article{0cf4f973dc9c4fc59789614117f18cf4,

title = "COVID-19 Breakthrough Infection Among Immunocompromised Persons",

author = "Kim, {Alfred H.J.} and Nakamura, {Mary C.}",

note = "Funding Information: reported receiving grants from GlaxoSmithKline, Rheumatology Research Foundation, Helmsley Charitable Trust National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health, and National Multiple Sclerosis Society outside the submitted work, as well as personal fees from GlaxoSmithKline, Aurinia Pharmaceuticals, and Exagen Diagnostics. Dr Nakamura reported owning stock in Moderna.",

year = "2022",

month = feb,

doi = "10.1001/jamainternmed.2021.7033",

language = "English",

volume = "182",

pages = "163--164",

journal = "JAMA Internal Medicine",

issn = "2168-6106",

number = "2",

}

TY - JOUR

T1 - COVID-19 Breakthrough Infection Among Immunocompromised Persons

AU - Kim, Alfred H.J.

AU - Nakamura, Mary C.

N1 - Funding Information: reported receiving grants from GlaxoSmithKline, Rheumatology Research Foundation, Helmsley Charitable Trust National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health, and National Multiple Sclerosis Society outside the submitted work, as well as personal fees from GlaxoSmithKline, Aurinia Pharmaceuticals, and Exagen Diagnostics. Dr Nakamura reported owning stock in Moderna.

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85122067148&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2021.7033

DO - 10.1001/jamainternmed.2021.7033

M3 - Comment/debate

C2 - 34962552

AN - SCOPUS:85122067148

SN - 2168-6106

VL - 182

SP - 163

EP - 164

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

IS - 2

ER -

COVID-19 Breakthrough Infection Among Immunocompromised Persons

Access to Document

Other files and links

Cite this